Research programme: selective estrogen receptor modulators - Karo Bio/Merck & Co

Drug Profile

Research programme: selective estrogen receptor modulators - Karo Bio/Merck & Co

Alternative Names: ER programme; Estrogen receptor modulators programme; SERM programme

Latest Information Update: 31 Jul 2013

Price : $50

At a glance

  • Originator Karo Bio
  • Developer Merck & Co
  • Class
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Female genital diseases; Menopausal syndrome; Postmenopausal osteoporosis

Most Recent Events

  • 30 Sep 2012 Discontinued - Preclinical for Postmenopausal osteoporosis in Sweden (unspecified route)
  • 30 Sep 2012 Discontinued - Preclinical for Menopausal syndrome in Sweden (unspecified route)
  • 30 Sep 2012 Discontinued - Preclinical for Gynaecological disorders in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top